|
| U.S. Brand
Names |
|
| Octocaine® Injection; Xylocaine®
With
Epinephrine |

|
|
| Generic
Available |
|
|
Yes |

|
|
| Synonyms |
|
|
Epinephrine and Lidocaine |

|
|
| Pharmacological Index |
|
|
Local Anesthetic |

|
|
| Use |
|
|
Dental: Amide-type anesthetic used for local infiltration anesthesia;
injection near nerve trunks to produce nerve block
Medical: Local infiltration anesthesia; AVS for nerve block
|

|
|
| Pregnancy Risk
Factor |
|
|
B |

|
|
| Contraindications |
|
|
Hypersensitivity to local anesthetics of the amide type, myasthenia gravis,
shock, or cardiac conduction disease |

|
|
| Warnings/Precautions |
|
|
Do not use solutions in distal portions of the body (digits, nose, ears,
penis); use with caution in endocrine, heart, hepatic, or thyroid
disease |

|
|
| Adverse
Reactions |
|
|
Refer to Lidocaine monograph |

|
|
| Overdosage/Toxicology |
|
|
Refer to Lidocaine monograph |

|
|
| Drug
Interactions |
|
|
Due to epinephrine component, use with tricyclic antidepressants or MAO
inhibitors could result in increased pressor response; use with nonselective
beta-blockers (ie, propranolol) could result in serious hypertension and reflex
bradycardia |

|
|
| Stability |
|
|
Solutions with epinephrine should be protected from
light |

|
|
| Mechanism of
Action |
|
|
Lidocaine blocks both the initiation and conduction of nerve impulses via
decreased permeability of sodium ions; epinephrine increases the duration of
action of lidocaine by causing vasoconstriction (via alpha effects) which slows
the vascular absorption of lidocaine |

|
|
| Pharmacodynamics/Kinetics |
|
|
Peak effect: Within 5 minutes
Duration: ~2 hours, dependent on dose and anesthetic procedure
|

|
|
| Usual Dosage |
|
|
Children: Use lidocaine concentrations of 0.5% to 1% (or even more diluted)
to decrease possibility of toxicity; lidocaine dose should not exceed 7
mg/kg/dose; do not repeat within 2 hours
Adults: Dosage varies with the anesthetic procedure, degree of anesthesia
needed, vascularity of tissue, duration of anesthesia required, and physical
condition of patient |

|
|
| Dietary
Considerations |
|
|
No data reported |

|
|
| Administration |
|
|
Before injecting, withdraw syringe plunger to ensure injection is not into
vein or artery |

|
|
| Dental Health: Local
Anesthetic/Vasoconstrictor
Precautions |
|
|
No information available to require special precautions |

|
|
| Dental Health:
Effects on Dental Treatment |
|
|
No effects or complications reported |

|
|
| Patient
Information |
|
|
See individual agents |

|
|
| Nursing
Implications |
|
|
Before injecting, withdraw syringe plunger to ensure injection is not into
vein or artery |

|
|
| Dosage Forms |
|
|
Injection with epinephrine:
1:100,000: Lidocaine hydrochloride 1% [10 mg/mL] (20 mL, 50 mL); 2% [20
mg/mL] (1.8 mL, 20 mL, 50 mL)
1:50,000: Lidocaine hydrochloride 2% [20 mg/mL] (1.8 mL)
|

|
|
| References |
|
|
Jastak JT and Yagiela JA,
"Vasoconstrictors and Local Anesthesia: A Review and Rationale for Use," J Am
Dent Assoc, 1983, 107(4):623-30.
MacKenzie TA and Young ER, "Local Anesthetic Update," Anesth Prog,
1993, 40(2):29-34.
Wynn RL, "Epinephrine Interactions With Beta-Blockers," Gen Dent,
1994, 42(1):16, 18.
Wynn RL, "Recent Research on Mechanisms of Local Anesthetics," Gen
Dent, 1995, 43(4):316-8.
Yagiela JA, "Local Anesthetics," Anesth Prog, 1991, 38(4-5):128-41.
|

|
|
Copyright © 2007 Drugs Area
|